Journal of Clinical Oncology
Articles in this Issue
Unraveling clonal hematopoiesis of indeterminate potential (CHIP) in cancer: Prevalence, clonal dynamics, and prognostic significance.
e22524 Background: CHIP prevalence in cancer (CA) patients (pts) is estimated at 30%, its presence being associated to higher risk of therapy-related myel...
A pilot randomized controlled trial of photobiomodulation therapy in head and neck cancer survivors with chronic lymphedema.
e18068 Background: Chronic lymphedema is a common late effect after completion of head and neck cancer (HNC) treatment, contributing to substantial sympto...
A multiregional, randomized, controlled, open-label, phase 3 study of the anti-claudin18.2 (CLDN18.2) antibody-drug conjugate (ADC) arcotatug tavatecan (IBI343) in gastric or gastroesophageal junction adenocarcinoma (G/GEJA): Trial in progress.
TPS4201 Background: CLDN18.2 has been a validated therapeutic target for G/GEJA. As a next-generation ADC, arcotatug tavatecan (IBI343) composed of anti-C...
Concurrent chemoradiotherapy with or without nimotuzumab in induction chemotherapy resistant locoregionally advanced nasopharyngeal carcinoma: An open-label randomised, controlled, phase 2 trial.
6064 Background: Induction chemotherapy (IC) followed by concurrent chemoradiotherapy (CCRT) is the current standard of care for locoregionally advanced n...
Efficacy and safety of pivekimab sunirine (PVEK) in patients (pts) with blastic plasmacytoid dendritic cell neoplasm (BPDCN) in the CADENZA study.
6502 Background: BPDCN is a rare, clinically aggressive hematological malignancy primarily involving the skin, bone marrow, and lymph nodes. CD123 (IL-3Rα...
Safety outcomes of intravenous immunoglobulin (IVIG) in treatment of steroid-refractory immune-checkpoint inhibitor pneumonitis.
2666 Background: Pneumonitis is a potentially severe adverse event of immune checkpoint inhibitors (ICIs). While the first line treatment for ICI pneumoni...
Breast cancer morbidity and role of mammographic screening program in Uzbekistan.
e22510 Background: Breast cancer (BC) is one of the most important socio - economic problem in Uzbekistan. BС is the most common disease and the main caus...
A retrospective study on potential cross-reactivity between hypersensitivity reactions to taxanes and fosaprepitant.
e24098 Background: Hypersensitivity reactions (HSRs) to taxanes are often linked to their solvents: Cremophor EL in paclitaxel and polysorbate 80 in docet...
Use of artificial intelligence (AI)–powered spatial analysis to predict pathologic complete response (pCR) in HR+ HER2- breast cancer (BC) patients treated with neoadjuvant chemotherapy (NAC).
593 Background: In the KEYNOTE(KN)-756 study, adding pembrolizumab to NAC increased pCR in high-risk HR+ HER2- BC. There is an unmet need to discover who...
Claudin18.2 (CLDN18.2) expression and efficacy in pancreatic ductal adenocarcinoma (PDAC): Results from a phase I dose expansion cohort evaluating IBI343.
4017 Background: CLDN18.2 is highly expressed in nearly 60% of PDAC cases. Yet to date, there are no approved targeted therapies and prognoses for these p...
Real world analysis of MGUS: Risk of progression and overall survival.
e19576 Background: MGUS is a premalignant condition for plasma cell malignancies (PCM) such as multiple myeloma (MM) and lymphoproliferative disorders (LP...
Cytokine-mediated hypersensitivity reactions to carboplatin in early triple-negative breast cancer with neoadjuvant pembrolizumab plus chemotherapy.
e12589 Background: High-grade fevers exceeding 40°C after administration of carboplatin and paclitaxel have occasionally been observed in early triple-neg...
Hypothyroidism related to immunotherapy in elderly adults: Analysis of a Colombian oncology cohort.
e24109 Background: Immunotherapy, including immune checkpoint inhibitors (ICIs), is a standard treatment for various cancers and has proven effective in o...
Survival impact of adjuvant chemotherapy regimens for small (T1mi/a/b), node-negative (pN0), triple-negative breast cancer (TNBC).
546 Background: While triple negative breast cancer (TNBC) represents an aggressive subtype of breast cancer worldwide, clinically low-risk cases are stil...
Real-world enfortumab vedotin +/- pembrolizumab (EV+/-P)–based treatment toxicity, treatment discontinuation, and associations with survival in advanced urothelial carcinoma (aUC).
4562 Background: EV-based therapy is central to the standard of care for aUC, increasingly in combination with P. Current understanding of EV-related toxi...
Duration and de-escalation of FOLFIRINOX as first-line chemotherapy in advanced pancreatic adenocarcinoma.
e16370 Background: ModifiedFOLFIRINOX (FFX) is a standard first-line (1L) chemotherapy regimen for advanced pancreatic cancer. Toxicity is common during F...
An open-label, multicenter, phase 1/2 study of peluntamig (PT217), an anti-DLL3/anti-CD47 bispecific antibody, in patients with DLL3-expressing cancers such as SCLC, LCNEC and EP-NEC (SKYBRIDGE study).
TPS8128 Background: Neuroendocrine carcinomas (NECs) are aggressive cancers with limited median survival. Over 90% of the NEC cases originate from the lun...
Ocular toxicity and tolerability of BCMA directed antibody drug conjugate (ADC) therapy in relapsed multiple myeloma (MM).
e19503 Background: The uptake of BCMA directed ADCs in MM has been hindered by ocular toxicity. Belantamab mafodotin (BM) and MEDI2228 (MEDI) are BCMA dir...
Integrated molecular characterization of pediatric soft tissue sarcomas: A report from the COG and CCDI molecular characterization initiative.
10025 Background: The Molecular Characterization Initiative (MCI), a partnership between the Children’s Oncology Group (COG) and the NCI’s Childhood Cance...
The importance of routine G6PD screening in oncology patients: A prospective comparative study in African American males (AAM) highlighting the additional benefits of pharmacogenomics (PGx) panels over standard enzyme assay.
e13838 Background: G6PD deficiency can cause acute hemolytic anemia due to oxidative stress in red blood cells triggered by medications. It has traditiona...
Circulating tumor DNA as a minimal residual disease assessment and recurrence risk in hepatocellular carcinoma: A systematic review and meta-analysis.
e15055 Background: Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and the mainstay of curative treatment for patients (pts) wi...
Relationship between FOLR1 expression and pan-cancer subgroup of tumors with specific transcriptomic profile.
3136 Background: Mirvetuximab soravtansine is an antibody–drug conjugate currently approved for the treatment of advanced platinum-resistant ovarian cance...
A phase 1 study of PARP inhibitor (niraparib) plus HSP90 inhibitor (pimitespib) in solid tumors: Dose-expansion results from the NiraPim (EPOC2102) study.
3079 Background: Heat shock protein 90 (HSP90) inhibitors have shown potential in destabilizing homologous recombination repair (HRR) proteins, thereby in...
Impact of trimodal therapy on survival outcomes in non-urothelial muscle-invasive bladder cancer: A nationwide analysis.
e16614 Background: Bladder-sparing strategies (BSS) are increasingly utilized in managing muscle-invasive bladder cancer (MIBC), with trimodal therapy (TM...
Impact of body mass index, diabetes, and tumor mutational burden in ovarian, fallopian tube, and primary peritoneal carcinoma with BRCA1/2 alteration on poly(ADP-ribose) polymerase inhibitors.
5585 Background: Obesity and hyperinsulinemia are associated with increased fallopian tube (FT) epithelial DNA damage in women carrying germline BRCA1/2 m...